STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Clinical trials for STAGE IIIA CUTANEOUS MELANOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA CUTANEOUS MELANOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA CUTANEOUS MELANOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF to the immunotherapy ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if the combination improved …
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
Triple-Drug attack shows promise for Tough-to-Treat melanoma
Disease control OngoingThis study tests two different three-drug combinations in people with advanced melanoma that has spread or can't be removed by surgery. The drugs include immunotherapy (nivolumab) plus targeted therapies that block cancer growth signals. The goal is to see if these combinations w…
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
Experimental combo targets cancer cell recycling in Late-Stage tumors
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
Two-Drug attack on tough melanoma shows early promise
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in 20 people with advanced melanoma that could not be surgically removed. The mai…
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy shows promise in advanced skin cancer trial
Disease control OngoingThis study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be removed by surgery. The goal was to see if the combination could delay cancer growth better than i…
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy gives hope to melanoma patients who failed standard treatment
Disease control OngoingThis study tests whether combining two immunotherapy drugs—T-VEC (a virus-based therapy injected into tumors) and pembrolizumab (an antibody given by IV)—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 43 adults with sta…
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find a dose that limits side effects while pot…
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Supercharged immune cells take on melanoma in early trial
Disease control OngoingThis early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …
Matched conditions: STAGE IIIA CUTANEOUS MELANOMA AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC